C.R. Bard (BCR) Shares are Down -1.54%

C.R. Bard (BCR) : During the past 4 weeks, traders have been relatively bearish on C.R. Bard (BCR), hence the stock is down -5.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.51% relative to the S&P 500. The 4-week change in the price of the stock is -4.75% and the stock has fallen -1.54% in the past 1 week.

CR Bard Inc. has dropped 0.19% during the last 3-month period . Year-to-Date the stock performance stands at 16.06%. The stock has recorded a 20-day Moving Average of 1.83% and the 50-Day Moving Average is 3.8%.


C.R. Bard (NYSE:BCR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $217.89 and $216.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $219.22. The buying momentum continued till the end and the stock did not give up its gains. It closed at $219.08, notching a gain of 0.44% for the day. The total traded volume was 545,611 . The stock had closed at $218.11 on the previous day.

Also, Equity Analysts at the Barclays maintains the rating on C.R. Bard (NYSE:BCR). The brokerage firm has issued a Equalweight rating on the shares. The Analysts at the ratings agency raises the price target from $224 per share to $235 per share. The rating by the firm was issued on July 27, 2016.

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.